Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Marker Therapeutics Reports Results From Phase 1 APOLLO Study Of MT-601 In Relapsed Lymphoma, Showing 78% Objective Response Rate And 44.4% Complete Responses With Well-Tolerated Safety Profile And No ICANS Observed

Author: Benzinga Newsdesk | December 19, 2024 09:16am

Posted In: MRKR